drugset
drugset / Trial / NCT06849778

An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis

NCT06849778 ↗

Phase 1 Completed 7 enrolled Taisho Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A phase 1, open-label, pharmacokinetic study of TS-172 in patients on hemodialysis

Timeline

Start
2025-03-22
Primary completion
2025-04-24
Completion
2025-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral

Indications

No indication recorded.